United Therapeutics CORP Form 4 insider transactions

Director Tommy G. Thompson exercised stock options and sold shares of United Therapeutics Corp on May 9, 2025.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on May 1, 2025, under a pre-arranged 10b5-1 trading plan.

Raymond Dwek, a director at United Therapeutics, exercised stock options and sold the resulting shares according to a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 17, 2025, according to a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised stock options and sold shares of United Therapeutics Corp on April 14, 2025, according to a Form 4 filing.

Director Raymond Dwek exercised stock options and sold the resulting shares of United Therapeutics Corp (UTHR) on April 7, 2025, under a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on April 3, 2025, according to a Form 4 filing with the SEC.

Director Tommy G. Thompson exercised stock options and sold shares of United Therapeutics Corp on March 24, 2025.

Director Christopher Patusky exercised stock options and sold shares of United Therapeutics Corp (UTHR) on March 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, reports a transfer of shares between family trusts in a recent SEC filing.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, executed share tracking awards and disposed of common stock under a pre-arranged 10b5-1 plan.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on March 3, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Director Ray Kurzweil exercised stock options and sold shares of United Therapeutics Corp on February 28, 2025.

Director Tommy G. Thompson exercised stock options and sold shares of United Therapeutics Corp on February 28, 2025.

Michael Benkowitz, President and COO of United Therapeutics, executed stock option exercises and sales of common stock on February 24, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards for 7,700 shares under a pre-arranged 10b5-1 plan.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock held in trusts, according to a Form 4 filing with the SEC.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on February 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards on February 6, 2025, according to a Form 4 filing.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on February 3, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Michael Benkowitz, President and COO of United Therapeutics, executed stock options and sold shares of common stock on January 27, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on January 21, 2025, according to a Form 4 filing.

Paul A. Mahon, EVP & General Counsel at United Therapeutics, executed a pre-arranged transaction involving share tracking awards, resulting in a change in beneficial ownership.

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on January 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Christopher Patusky exercised stock options and sold shares of United Therapeutics Corp (UTHR) on January 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Michael Benkowitz, President and COO of United Therapeutics, executed stock options and sold shares of common stock on January 6, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards for 7,700 shares under a pre-arranged 10b5-1 plan.

United Therapeutics' President and COO, Michael Benkowitz, executed stock option exercises and subsequent sales of common stock under a pre-arranged 10b5-1 trading plan.

A director at United Therapeutics Corp sold 255 shares of common stock at a price of $355.7651 per share on December 30, 2024.